Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Programs Slides ▼About

Anticoagulation ▼Diabetes & CVD ▼Heart Failure ▼Kidney disease & CVD ▼Lipids ▼

Continue reading:

Anticoagulation

Results with novel FXI inhibitor in AF set the stage for phase 3 trials

3' education - Nov. 16, 2023 - Christian Ruff, MD

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD

DOAC reduces stroke in patients with subclinical atrial fibrillation

News - Nov. 12, 2023

Diabetes & CVD

GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications

3' education - Nov. 13, 2023 - Michael Lincoff, MD

GLP-1RA reduces risk of CV events associated with overweight and obesity

3' education - Nov. 11, 2023 - Michael Lincoff, MD

Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD

3' education - Nov. 11, 2023 - Ania Jastreboff, MD, PhD

Heart Failure

Having multiple non-cardiac comorbidities does not limit optimization of HF therapies

Literature - Nov. 27, 2023 - Chioncel O, et al. - Eur J Heart Fail. 2023

Management of hyperkalemia in CKD and HFrEF

15' education - Nov. 27, 2023 - George L. Bakris, MD, David Bushinsky, MD, and Lars Lund, MD

Clinical implications of the evidence from IV iron trials in HF

10' education - Nov. 15, 2023 - Stefan Anker, MD, PhD, Robert Mentz, MD, and Piotr Ponikowski, MD, PhD

Kidney disease & CVD

Management of hyperkalemia in CKD and HFrEF

15' education - Nov. 27, 2023 - George L. Bakris, MD, David Bushinsky, MD, and Lars Lund, MD

Combination of SGLT2i and nonsteroidal MRA improves estimated event-free survival in T2D and CKD

Literature - Nov. 7, 2023 - Heerspink HJL et al. - Diabetes Obes Metab. 2023

Reduction in albuminuria with aldosterone synthase inhibitor on top of SGLT2i in CKD

News - Nov. 7, 2023

Lipids

Elderly people also benefit from lipid-lowering therapy for primary prevention

Literature - Nov. 27, 2023 - Andersson NW, et al. - J Am Coll Cardiol. 2023

Phase 3 trial does not confirm efficacy of PCSK9 siRNA in HoFH

Literature - Nov. 20, 2023 - Raal F, et al. - Circulation. 2023

Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD

Obesity

GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications

3' education - Nov. 13, 2023 - Michael Lincoff, MD

GLP-1RA reduces risk of CV events associated with overweight and obesity

3' education - Nov. 11, 2023 - Michael Lincoff, MD

Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD

3' education - Nov. 11, 2023 - Ania Jastreboff, MD, PhD

© 2006 - 2023 pace-cme.org - About